<DOC>
	<DOC>NCT00126230</DOC>
	<brief_summary>This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.</brief_summary>
	<brief_title>Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>Patients older than 18 years and less than 80 years Histologicallyproven adenocarcinoma of the prostate Evidence of bone metastases and progressive, hormonerefractory, disease No previous chemotherapy No previous radiotherapy, except radiotherapy directed to the prostate and/or to a single bony lesion No previous carcinoma, except basalcell carcinoma of the skin Adequate renal function: measured or calculated creatinine clearance &gt; 60 ml/min Absolute granulocyte count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5 fold the upper normal value Signed informed consent. Patients infected by the Human Immunodeficiency Virus (HIV) Patients who do not fit inclusion criteria</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine</keyword>
</DOC>